Debanjan Ray, Chief Financial Officer at CytomX Therapeutics, Inc. (CTMX), sold 3,000 shares at $15.00 ($45K) on 2018-11-01, disclosed to the SEC on 2018-11-05.
Scheduled sale ($45k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| CTMX | SELL | 2018-09-06 | $67K | — | Filing → |
| CTMX | SELL | 2018-08-02 | $78K | — | Filing → |
| CTMX | SELL | 2018-07-03 | $68K | — | Filing → |